Get started
CITIUS PHARMACEUTICALS INCCITIUS PHARMACEUTICALS INCCITIUS PHARMACEUTICALS INC

CITIUS PHARMACEUTICALS INC

No trades
See on Supercharts
Overview
Financials News Ideas Minds Technicals Forecast

47N chart

Upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats

Market capitalization
‪103.60 M‬EUR
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.22EUR
Net income (FY)
‪−30.79 M‬EUR
Revenue (FY)
—
Shares float
‪166.70 M‬
Beta (1Y)
0.28

About Citius Pharmaceuticals, Inc.

Sector
Health Technology
Industry
Medical Specialties
CEO
Leonard L. Mazur
Website
citiuspharma.com
Headquarters
Cranford
Employees (FY)
22
Founded
2007
FIGI
BBG00RQ7YHL8
Citius Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of critical care products, with a focus on oncology, anti-infectives in adjunct cancer care, prescription products, and stem cell therapy. Its products include I/ONTAK, Mino-Lok, Halo-Lido, Mino-Wrap, and Novecite. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

Financials

Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas

See all ideas 

News

Keep reading

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating

An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Stock brokers

Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.

Frequently Asked Questions

The current price of 47N is 0.60 EUR — it hasn't changed in the past 24 hours. Watch CITIUS PHARMACEUTICALS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange CITIUS PHARMACEUTICALS INC stocks are traded under the ticker 47N.
47N stock has risen by 2.67% compared to the previous week, the month change is a 6.07% fall, over the last year CITIUS PHARMACEUTICALS INC has showed a 48.35% decrease.
We've gathered analysts' opinions on CITIUS PHARMACEUTICALS INC future price: according to them, 47N price has a max estimate of 3.71 EUR and a min estimate of 3.71 EUR. Watch 47N chart and read a more detailed CITIUS PHARMACEUTICALS INC stock forecast: see what analysts think of CITIUS PHARMACEUTICALS INC and suggest that you do with its stocks.
47N reached its all-time high on Jun 22, 2021 with the price of 3.74 EUR, and its all-time low was 0.56 EUR and was reached on May 29, 2024. View more price dynamics on 47N chart.
See other stocks reaching their highest and lowest prices.
47N stock is 0% volatile and has beta coefficient of 0.28. Track CITIUS PHARMACEUTICALS INC stock price on the chart and check out the list of the most volatile stocks — is CITIUS PHARMACEUTICALS INC there?
Today CITIUS PHARMACEUTICALS INC has the market capitalization of ‪107.99 M‬, it has decreased by 7.53% over the last week.
Yes, you can track CITIUS PHARMACEUTICALS INC financials in yearly and quarterly reports right on TradingView.
CITIUS PHARMACEUTICALS INC is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
47N earnings for the last quarter are −0.05 EUR per share, whereas the estimation was −0.05 EUR resulting in a 9.09% surprise. The estimated earnings for the next quarter are −0.05 EUR per share. See more details about CITIUS PHARMACEUTICALS INC earnings.
CITIUS PHARMACEUTICALS INC revenue for the last quarter amounts to 0 EUR, matching the estimated figure, and no changes in revenue are expected for the next quarter.
47N net income for the last quarter is ‪−7.92 M‬ EUR, while the quarter before that showed ‪−8.36 M‬ EUR of net income which accounts for 5.32% change. Track more CITIUS PHARMACEUTICALS INC financial stats to get the full picture.
No, 47N doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 12, 2024, the company has 22.00 employees. See our rating of the largest employees — is CITIUS PHARMACEUTICALS INC on this list?
Like other stocks, 47N shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CITIUS PHARMACEUTICALS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CITIUS PHARMACEUTICALS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CITIUS PHARMACEUTICALS INC stock shows the sell signal. See more of CITIUS PHARMACEUTICALS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.